STD confirmed to be associated with increased risk of prostate cancer
Key points
- Researchers confirmed previous findings that the sexual transmitted infection known as Trichomonas vaginalis is associated with an increased risk of prostate cancer in a study published online September 9 in the Journal of the National Cancer Institute.
- Jennifer Rider Stark, ScD, of the department of epidemiology at the Harvard School of Public Health in Boston, and colleagues conducted a case-control study nested within the Physicians' Health Study that included 673 case subjects with prostate cancer and 673 individually matched control subjects.
- Although not statistically significant, the size of the association between T. vaginalis–seropositive status and overall prostate cancer risk was similar to that reported previously.
- "If our findings are confirmed, T. vaginalis could serve as a marker for adverse outcomes in patients for prostate cancer or, more optimistically as a target for secondary chemoprevention," the authors write.
Researchers confirmed previous findings that the sexual transmitted infection known as Trichomonas vaginalis is associated with an increased risk of prostate cancer in a study published online September 9 in the Journal of the National Cancer Institute.
Jennifer Rider Stark, ScD, of the department of epidemiology at the Harvard School of Public Health in Boston, and colleagues conducted a case-control study nested within the Physicians' Health Study that included 673 case subjects with prostate cancer and 673 individually matched control subjects. Plasma was assayed for antibodies against T. vaginalis. The relationship of incident prostate cancer, extraprostatic prostate cancer, and cancer predicted to progress to bony metastases or prostate cancer–specific death was investigated.
Although not statistically significant, the size of the association between T. vaginalis–seropositive status and overall prostate cancer risk was similar to that reported previously. A seropositive status was associated with statistically significantly increased risks of extraprostatic prostate cancer and cancer that is likely to progress to bony metastases or prostate cancer–specific death.
"If our findings are confirmed, T. vaginalis could serve as a marker for adverse outcomes in patients for prostate cancer or, more optimistically as a target for secondary chemoprevention," the authors write.
In an accompanying editorial, Peter C. Albertsen, M.D., of the University of Connecticut Health Center, in Farmington, Conn., said that this study is another example of assessing a specific variable to determine the risk of prostate cancer that deserves serious attention.
"Unfortunately, an unintended consequence of prostate-antigen testing is the large number of men diagnosed with incidental disease that now confounds our ability to identify potential causes of clinically significant disease," writes the editorialist, who also pointed out that a much larger study would be required to detect a statistically significant difference between seropositivity and overall prostate cancer risk.
###
Contacts:
Article: Todd R. Datz, tdatz@hsph.harvard.edu, 617.432.3952
Editorial: Peter C. Albertsen, Albertsen@NSO.UCHC.EDU
Note to Reporters:
The Journal of the National Cancer Institute is published by Oxford University Press and is not affiliated with the National Cancer Institute. Attribution to the Journal of the National Cancer Institute is requested in all news coverage.
Visit JNCI online at http://jnci.oxfordjournals.org and the JNCI press room at http://www.oxfordjournals.org/our_journals/jnci/press_room.html
For the latest cancer news and studies, follow our Twitter account @JNCI_Now!
Contact: Steve Graff
Written and revised by
David Cohen, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Cancer →
NewsComponent in green tea may help reduce prostate cancer in men at high risk
Prostate cancer is the second most common type of cancer in men and is predicted to result in an estimated 220,00 cases in the United States in 2015. In recent years, an emphasis has been placed on chemoprevention - the…
30 May 2015
NewsFitness level associated with lower risk of some cancers, death in men
Men with a high fitness level in midlife appear to be at lower risk for lung and colorectal cancer, but not prostate cancer, and that higher fitness level also may put them at lower risk of death if they are diagnosed…
27 March 2015
NewsMoffitt researchers discover biological markers associated with high-risk pancreatic lesions
Pancreatic cancer affects approximately 46,000 people each year in the United States and ranks fourth among the leading causes of cancer-related deaths. Only about 6 percent of individuals with pancreatic cancer will…
